Scarica l'app Stockscreener
16.97
4.98%
-0.89
Pre-mercato:
16.40
-0.57
-3.36%
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week LowShould You Sell? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 7%Here's What Happened - MarketBeat
Swiss National Bank Sells 2,900 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading 6.5% HigherStill a Buy? - MarketBeat
Charles Schwab Investment Management Inc. Acquires 1,092 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Deep Track Capital, LP Acquires Significant Stake in Dianthus Th - GuruFocus
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8%Here's What Happened - MarketBeat
Avidity Partners Management LP Increases Stake in Dianthus Thera - GuruFocus
Cantor Fitzgerald Issues Positive Estimate for DNTH Earnings - MarketBeat
HC Wainwright Brokers Raise Earnings Estimates for DNTH - MarketBeat
FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for DNTH - MarketBeat
HC Wainwright Issues Optimistic Outlook for DNTH Earnings - Defense World
HC Wainwright Reaffirms "Buy" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
FY2025 EPS Estimates for DNTH Raised by Cantor Fitzgerald - Defense World
Dianthus Therapeutics' (DNTH) Outperform Rating Reiterated at Wedbush - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownWhat's Next? - MarketBeat
Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.5%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Research Analysts Set Expectations for DNTH Q1 Earnings - Defense World
HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Guggenheim Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Wedbush Reaffirms “Outperform” Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - MSN
Dianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate - Yahoo Finance
Dianthus Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday - Defense World
Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress - TipRanks
Stifel maintains Buy rating on Dianthus Therapeutics stock By Investing.com - Investing.com Canada
Dianthus Therapeutics shares fall as Q4 results miss expectations By Investing.com - Investing.com South Africa
Dianthus Therapeutics shares fall as Q4 results miss expectations - Investing.com India
Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress - TipRanks
Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating - TipRanks
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Brokerages - Defense World
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):